Abstract

BackgroundDuchenne Muscular Dystrophy (DMD) is characterized by increased muscle damage and an abnormal blood flow after muscle contraction: the state of functional ischemia. Until now, however, the cause-effect relationship between the pathogenesis of DMD and functional ischemia was unclear. We examined (i) whether functional ischemia is necessary to cause contraction-induced myofiber damage and (ii) whether functional ischemia alone is sufficient to induce the damage.Methodology/Principal Findings In vivo microscopy was used to document assays developed to measure intramuscular red blood cell flux, to quantify the amount of vasodilatory molecules produced from myofibers, and to determine the extent of myofiber damage. Reversal of functional ischemia via pharmacological manipulation prevented contraction-induced myofiber damage in mdx mice, the murine equivalent of DMD. This result indicates that functional ischemia is required for, and thus an essential cause of, muscle damage in mdx mice. Next, to determine whether functional ischemia alone is enough to explain the disease, the extent of ischemia and the amount of myofiber damage were compared both in control and mdx mice. In control mice, functional ischemia alone was found insufficient to cause a similar degree of myofiber damage observed in mdx mice. Additional mechanisms are likely contributing to cause more severe myofiber damage in mdx mice, suggestive of the existence of a “two-hit” mechanism in the pathogenesis of this disease.Conclusions/SignificanceEvidence was provided supporting the essential role of functional ischemia in contraction-induced myofiber damage in mdx mice. Furthermore, the first quantitative evidence for the “two-hit” mechanism in this disease was documented. Significantly, the vasoactive drug tadalafil, a phosphodiesterase 5 inhibitor, administered to mdx mice ameliorated muscle damage.

Highlights

  • Duchenne Muscular Dystrophy (DMD) is caused by the lack of a gene product, dystrophin [1], and affects approximately one in 3,500 male births [2]

  • In this study blood flow regulation in the pathogenesis of muscular dystrophy was evaluated using in vivo microscopic assays: we examined how blood flow responds to muscle contraction in mdx and control mice, whether Nitric oxide (NO)/H2O2 production in muscles is attenuated in mdx mice, and whether augmenting the nitric oxide pathway can prevent functional ischemia and the myofiber damage in mdx mice

  • Various parameters exist for the analysis of local blood flow, including RBC flux, RBC velocity, plasma flow, blood vessel diameter and functional capillary density

Read more

Summary

Introduction

Duchenne Muscular Dystrophy (DMD) is caused by the lack of a gene product, dystrophin [1], and affects approximately one in 3,500 male births [2]. In response to contractile workload, normal muscles endeavor to increase the blood flow to meet the muscular metabolic demands [6]. Duchenne Muscular Dystrophy (DMD) is characterized by increased muscle damage and an abnormal blood flow after muscle contraction: the state of functional ischemia. Reversal of functional ischemia via pharmacological manipulation prevented contraction-induced myofiber damage in mdx mice, the murine equivalent of DMD. This result indicates that functional ischemia is required for, and an essential cause of, muscle damage in mdx mice. Evidence was provided supporting the essential role of functional ischemia in contraction-induced myofiber damage in mdx mice. The vasoactive drug tadalafil, a phosphodiesterase 5 inhibitor, administered to mdx mice ameliorated muscle damage

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call